ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRY ARS PHARMACEUTICALS INC

Post-Mkt 06-12 16:40:19 EDT

9.76

+0.17

+1.77%

盘后9.76

+0.000.00%

16:10 EDT

High10.17	Low9.66	Vol1.32M
Open9.73	D1 Closing9.59	Amplitude5.32%
Mkt Cap964.76M	Tradable Cap539.44M	Total Shares98.85M
T/O13.02M	T/O Rate2.40%	Tradable Shares55.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":9.76,"timestamp":1781294400000,"preClose":9.59,"halted":0,"volume":1323943,"hourTrading":{"tag":"盘后","latestPrice":9.76,"preClose":9.76,"latestTime":"16:10 EDT","volume":1759,"amount":17167.84,"timestamp":1781295005057,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01772679874869655,"floatShares":55270496,"shares":98848611,"eps":-2.004377,"marketStatus":"Post-Mkt","change":0.17,"latestTime":"06-12 16:40:19 EDT","open":9.73,"high":10.17,"low":9.66,"amount":13023518,"amplitude":0.05318,"askPrice":11.05,"askSize":100,"bidPrice":8.68,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.004377,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1781308800000},"marketStatusCode":4,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":9.59,"preHourTrading":{"tag":"盘前","latestPrice":9.72,"preClose":9.59,"latestTime":"09:29 EDT","volume":24569,"amount":238181.369634,"timestamp":1781270969005,"change":0.13,"changeRate":0.013556,"amplitude":0.133472},"postHourTrading":{"tag":"盘后","latestPrice":9.76,"preClose":9.76,"latestTime":"16:10 EDT","volume":1759,"amount":17167.84,"timestamp":1781295005057,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.011019,"impliedVol":0.9483,"impliedVolPercentile":0.502},"requestUrl":"/m/hq/s/SPRY/wiki","defaultTab":"wiki","newsList":[{"id":"2640152461","title":"Drew Brees Collaborates With ARS Pharmaceuticals to Raise Awareness About Living Life With Severe Allergies","url":"https://stock-news.laohu8.com/highlight/detail?id=2640152461","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640152461?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:00","pubTimestamp":1780574404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA7VT5QZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640645962","title":"ARS Pharmaceuticals files Form 3 for President Donn Casale, reporting no beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2640645962","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640645962?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:43","pubTimestamp":1780346585,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals President Donn Casale filed an initial Form 3 beneficial ownership statement on June 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL2NQ65n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638691993","title":"ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2638691993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638691993?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:17","pubTimestamp":1779977820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2026 10:17 ET (14:17 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635080347","title":"ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635080347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635080347?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:30","pubTimestamp":1778851856,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 61 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081584","title":"BUZZ-U.S. STOCKS ON THE MOVE-Cerebras, Papa John's, airline stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081584","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081584?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:52","pubTimestamp":1778845928,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Cerebras, Papa John's, airline stocks  Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL6N41S0TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456854461.SGD","BK4077","ALK","GFI","AU","LU0143863198.USD","LU0266013472.USD","SPRY","LU0143863784.USD","LU1102505929.USD","BK4122","CBRS","BK4504","LU2087625088.SGD","LU0052756011.USD","LU0630314457.HKD","LU1280957306.USD","LU0612318971.USD","LU1223083913.SGD","BK4082","BK4522","LU0640476718.USD","PZZA","BK4570","LU0075056555.USD","LU2210149790.SGD","LU0724618789.USD","NEM","LU1223082196.USD","BK4585","LU0266512473.USD","BK4532","BK4551","LU2498475776.HKD","LU0368265764.SGD","BK4023","IE00B19Z3B42.SGD","GEMG","LU0496367417.USD","LU1267930227.SGD","LU1323610961.USD","LU0170899867.USD","LU0330918003.SGD","DAL","LU1223082519.USD","LU2125909593.SGD","IE00BMPRXN33.USD","LU0788109121.HKD","LU1102505762.USD","LU0654597011.USD","DXCM","LU0353189680.USD","LU1923622614.USD","ORRF","BK4500","LUV","LU0055631609.USD","BK4533","NEMG","BK4211","LU0303821028.USD","IE00BFMHRM44.USD","FIG","LU0788108826.HKD","LU0354030438.USD","LU1868837565.USD","LU2210150020.SGD","LU0128525689.USD","BK4534","GETY","LU0300736492.USD","LU0345780521.USD","BK4112","SG9999001143.SGD","LU0345781412.USD","BK4017","HMY","LU0498741114.HKD","LU0498741890.SGD","LU2065731478.USD","FIGG","LU1868838027.USD","IE00B19Z3581.USD","LU0266512127.USD","LU0345780281.USD","UAL","LU1023059493.AUD","IE00BMPRXR70.SGD","LU0354030511.USD","BK4548","LU0310800965.SGD","LU0353189763.USD","LU2433249047.HKD","NWMX","LU0303823156.USD","BK4139","LU0300736062.USD","GEMI","LU2462611646.USD","LU0612318385.USD","LU0278409577.USD","LU2211815571.USD","LU1430597077.USD","LU2125909247.SGD","LU0345780950.USD","SSTK","LU1883866441.USD","BK4209","BK4008","LU2095319765.USD","IE0002270589.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083955","title":"ARS Pharma Q1 FY26 net loss widens to $60.62 million; revenue more than doubled to $22.68 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083955","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635083955?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:23","pubTimestamp":1778840583,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals posted Q1 net loss of USD 60.62 million, widening 79% from year-earlier period as revenue more than doubled to USD 22.68 million.Product revenue, net climbed 125% to USD 17.45 million; revenue under collaboration agreements rose to USD 2.49 million.Operating loss widened 62% to USD 60.15 million, while selling, general and administrative expense increased 76% to USD 72.2 million.Commercial launch metrics showed about 120,000 patients using neffy in the U.S. at quarter-end, with about 29,500 added during the quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLbD7F0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083134","title":"ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083134","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635083134?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:19","pubTimestamp":1778840391,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  reported a Q1 net loss Friday of $0.61 per diluted share, widening from a loss of $0.35 a year earlier.Two analysts polled by FactSet expected a loss of $0.49.Revenue for the quarter ended March 31 was $22.7 million, compared with $8 million a year earlier.Analysts surveyed by FactSet expected $22.2 million.The company had $201 million in cash, cash equivalents, and short-term investments as of March 31, expected to fund operations through cash-flow break-even, it said.ARS shares were up 2.4% in premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635008874","title":"ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2635008874","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635008874?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:12","pubTimestamp":1778839922,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growthOverviewU.S. biopharma firm's Q1 revenue rose yr/yr, beating analyst expectationsCompany's Q1 net loss widened as operating expenses","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BSNM7G36.USD","LU0208291251.USD","CVS","LU2125909247.SGD","LU0211331839.USD","LU1059921491.USD","LU0320765489.SGD","IE00B19Z3581.USD","LU2433249047.HKD","LU2125909593.SGD","IE0002270589.USD","LU0070302665.USD","BK4588","BK4585","BK4196","IE00BKVL7J92.USD","LU1983299246.USD","LU1571399168.USD","LU0072461881.USD","LU1699723380.USD","LU0061475181.USD","BK4581","IE00B19Z3B42.SGD","BK4550","BK4504","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU0432979614.USD","SPRY","LU0006061336.USD","LU0162691827.USD","LU1923622614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088480","title":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088480?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:06","pubTimestamp":1778839583,"startTime":"0","endTime":"0","summary":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635886670","title":"ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635886670","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635886670?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:03","pubTimestamp":1778839382,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 74.29 percent decrease over losses of $(0.35) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52590032/ars-pharmaceuticals-q1-eps-0-61-misses-0-52-estimate-sales-22-681m-beat-22-230m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635885950","title":"ARS Pharmaceuticals: Anticipate Majority of Medicaid State Plans Adopting Neffy to Their Unrestricted Medicaid Formularies by Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2635885950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635885950?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX027E32:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635391088","title":"ARS Pharmaceuticals Q1 Net Income USD -60.618 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635391088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635391088?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX027E32:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635208836","title":"ARS Pharmaceuticals Q1 Cash & Investments USD 201 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635208836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635208836?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX027E32:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088399","title":"ARS Pharmaceuticals Inc: CVS Caremark Proposal in Final Stages of Approval Process; Definitive Update Anticipated in Early June","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088399?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX027E32:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088359","title":"ARS Pharmaceuticals Q1 EPS USD -0.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088359?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX027E32:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088318","title":"ARS Pharmaceuticals Q1 Revenue USD 22.7 Million VS. Ibes Estimate USD 22.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088318?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX027E32:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908869","title":"Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908869","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635908869?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":"Q1 2026 total revenue of $22.7 million including neffy  U.S. net product. CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June. Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout. Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET. SAN DIEGO, May 15, 2026  -- ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2026 and provided an update on the continued commercialization of neffy , the first and only FDA- and European Commission-approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis.the first quarter of 2026 were $72.2 million, reflecting continued","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SPRY","R","BK4008","BK4588","BK4232","ALK","BK4139","BK4500","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635707744","title":"U.S. Earnings Preview: Before Market Open May 15","url":"https://stock-news.laohu8.com/highlight/detail?id=2635707744","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635707744?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:31","pubTimestamp":1778837460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results before the market opens.RBC Bearings Inc.'s fourth-quarter EPS is forecast at $2.72, compared with $2.30 in the prior-year period. Adjusted EPS is forecast at $3.33.ARS Pharmaceuticals Inc.'s first-quarter EPS is forecast at a loss of 49 cents, compared with a loss of 35 cents in the prior-year period. Adjusted EPS is forecast at a loss of 52 cents.Lument Finance Trust Inc.'s first-quarter EPS is forecast at 1 cent, compared with a loss of 3 cents in the prior-year period. Adjusted EPS is forecast at 6 cents.Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4139","LU2065731478.USD","RBC","SPRY","IE00BD6J9T35.USD","BK4110","IE00B64QTZ34.USD","LFT","IE00BLDYK493.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635709887","title":"ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2635709887","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635709887?lang=en_us&edition=fundamental","pubTime":"2026-05-15 14:08","pubTimestamp":1778825313,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52588230/ars-pharmaceuticals-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635879770","title":"Dow Settles Above 50,000: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone","url":"https://stock-news.laohu8.com/highlight/detail?id=2635879770","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635879770?lang=en_us&edition=fundamental","pubTime":"2026-05-15 14:01","pubTimestamp":1778824870,"startTime":"0","endTime":"0","summary":"The CNN Business Fear &amp; Greed Index, a measure of market sentiment, improved slightly on Thursday but remains in the Greed zone at 66.1.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/05/52588184/dow-settles-above-50000-investor-sentiment-improves-fear-index-remains-in-greed-zone","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1221951129.SGD","BK4132","LU2247934214.USD","IE00B64QTZ34.USD","BK4533","LU1066051811.HKD","LU1674673428.USD","LU2237443978.SGD","BK4560","SPRY","LU1571399168.USD","SURG","LU1244550577.SGD","RBC","SG9999015978.USD","IE00BZ1G4Q59.USD","LU1235294995.USD","CSCO","BK4515","IE00BD6J9T35.USD","IE00BVYPNV92.GBP","LU1244550494.USD","LU1894683264.USD","LU0731783394.SGD","LU0792757196.USD","CSCL","LU0203347892.USD","LU2237443382.USD","LU2237443622.USD","SG9999001424.SGD","BK4588","BK4220","CSCS","LU0234570918.USD","DDS","LU1585245621.USD","LU1162221912.USD","LU0868494617.USD","LU2456880835.USD","LU2506951875.HKD","SG9999015952.SGD","LU0098860793.USD","LU2102340556.USD","LU2417539215.USD","LU1778281490.HKD","IE00BFXG1179.USD","LU1032955483.USD","LU1059921491.USD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":0.0573},{"period":"1month","weight":0.1112},{"period":"3month","weight":0.143},{"period":"6month","weight":-0.0635},{"period":"1year","weight":-0.3312},{"period":"ytd","weight":-0.1768}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.048654},{"month":2,"riseRate":0.5,"avgChangeRate":0.059864},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.043227},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.065084},{"month":5,"riseRate":0.833333,"avgChangeRate":0.033934},{"month":6,"riseRate":0.666667,"avgChangeRate":0.087424},{"month":7,"riseRate":0.8,"avgChangeRate":0.11695},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080641},{"month":9,"riseRate":0.2,"avgChangeRate":-0.212128},{"month":10,"riseRate":0.4,"avgChangeRate":-0.021216},{"month":11,"riseRate":0.4,"avgChangeRate":0.043601},{"month":12,"riseRate":0.6,"avgChangeRate":0.080317}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}